Physician

David A. Knight, MD, PHD.

According to 2025 Medicare claims, David Knight, MD, PHD. (NPI: 1598969644) practices hematology/oncology in the Kenosha, WI market, with the plurality of this provider's patient population coming from Kenosha, WI. This provider's primary affiliated billing organization is FROEDTERT SOUTH, INC. (NPI: 1558305284; TIN: 390816845) and primary practice location at 53158-1984.

Knight's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 533 traditional Medicare patients, billed 4,302 HCPCS/CPT codes, and received $268,990 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,597 prescription claims across 443 beneficiaries totaling $6,049,465 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 28 claims. Open Payments data shows 4 records totaling $116. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $83,843 to $268,990. Similarly, Part D prescription costs have risen steadily, from $825,887 to $6,049,465. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $4,413 and ending at $1,173.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	263	987	$83,843
2016	284	1,142	$91,447
2017	483	1,829	$135,429
2018	616	2,974	$239,517
2019	610	3,040	$247,928
2020	510	2,445	$193,556
2021	490	2,940	$294,254
2022	634	3,280	$291,690
2023	603	2,871	$237,073
2024	533	4,302	$268,990

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	105	934	$825,887
2016	140	1,381	$1,497,599
2017	233	1,848	$2,449,636
2018	304	2,242	$4,032,221
2019	317	2,365	$3,970,771
2020	309	2,177	$4,323,832
2021	312	1,982	$4,673,580
2022	345	2,074	$4,729,380
2023	395	2,207	$5,281,375
2024	443	2,597	$6,049,465

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	62	$15,889
2016	N/R	45	$1,116
2017	N/R	71	$12,983
2018	N/R	30	$4,273
2019	N/R	N/R	N/R
2020	N/R	24	$900
2021	N/R	48	$1,775
2022	N/R	95	$3,476
2023	N/R	28	$1,121
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	314	868	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	339	991	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	148	165	$59
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	104	177	$24
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	434	1,549	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	58	1,622	$1,071,568
Calquence	Acalabrutinib Maleate	47	1,394	$636,532
Ibrance	Palbociclib	38	1,057	$586,844
Cabometyx	Cabozantinib S-Malate	24	720	$584,497
Jakafi	Ruxolitinib Phosphate	31	915	$434,325

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$116	TAIHO ONCOLOGY, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David A. Knight, MD, PHD.?

Tedicare shows public-source Medicare data for David A. Knight, MD, PHD. (NPI 1598969644), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David A. Knight, MD, PHD. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David A. Knight, MD, PHD.?

David A. Knight, MD, PHD. is linked to FROEDTERT SOUTH, INC. (billing NPI 1558305284) in the available physician profile data.

Does David A. Knight, MD, PHD. have Open Payments data?

David A. Knight, MD, PHD. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.